Fujita K, Sakata H, Yoshioka H
Pediatr Infect Dis. 1984 Nov-Dec;3(6):530-3. doi: 10.1097/00006454-198411000-00010.
Fecal flora of nine pediatric inpatients who were receiving trimethoprim-sulfamethoxazole were studied by quantitative aerobic and anaerobic culture methods. During the course of trimethoprim-sulfamethoxazole, the number of Enterobacteriaceae decreased from 10(8-9) to 10(4-5) bacteria per g feces. The isolation rate and the number of Veillonella were also reduced. Other prominent aerobic and anaerobic flora, including Streptococcus, Bacteroidaceae and Bifidobacterium, were not affected. No overgrowth of Pseudomonas, Staphylococcus, Candida or Clostridium was noted. These results support the usefulness of oral trimethoprim-sulfamethoxazole for the prophylaxis of bacterial infection in the compromised host.
采用定量需氧和厌氧培养方法，对9名正在接受甲氧苄啶 - 磺胺甲恶唑治疗的儿科住院患者的粪便菌群进行了研究。在接受甲氧苄啶 - 磺胺甲恶唑治疗期间，每克粪便中肠杆菌科细菌数量从10(8 - 9) 降至10(4 - 5)。韦荣球菌的分离率和数量也有所降低。其他主要的需氧和厌氧菌群，包括链球菌、拟杆菌科和双歧杆菌，未受影响。未观察到假单胞菌、葡萄球菌、念珠菌或梭菌的过度生长。这些结果支持口服甲氧苄啶 - 磺胺甲恶唑对预防免疫功能低下宿主的细菌感染有效。
